|
AU4863900A
|
|
Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
|
|
US6060309A
|
|
Immune mediators and related methods
|
|
AU2605097A
|
|
Cyclic peptide vaccines for treatment and prevention of diabetes
|
|
WO9640194A1
|
|
Stable formulations of mhc-peptide complexes
|
|
US5750356A
|
|
Method for monitoring T cell reactivity
|
|
US5824315A
|
|
Binding affinity of antigenic peptides for MHC molecules
|
|
EP0792157A1
|
|
Preparation of mhc-peptide complexes
|
|
US5734023A
|
|
MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
|
|
US6045796A
|
|
Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
|
|
US6106840A
|
|
MHC conjugates useful in ameliorating autoimmunity
|
|
WO9511702A1
|
|
Prokaryotic expression of mhc proteins
|
|
US5595881A
|
|
Method for the detection of antigen presenting cells
|
|
US5763585A
|
|
Method of making MHC-peptide complexes using metal chelate affinity chromatography
|
|
AU6270794A
|
|
Treatment of allergic responses using mhc-peptide complexes
|
|
AU3220693A
|
|
Mhc subunit conjugates useful in ameliorating deleterious immune responses
|
|
WO9310220A1
|
|
Soluble mhc molecules and their uses
|
|
EP0630255A1
|
|
Mhc conjugates useful in ameliorating autoimmunity
|
|
US5260422A
|
|
MHC conjugates useful in ameliorating autoimmunity
|
|
US5130297A
|
|
Conjugates useful in ameliorating autoimmunity MHC-II-peptide
|
|
US5169934A
|
|
Intracellularly cleavable compounds
|
